Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
In Merck's press release today:
Select Business Highlights
•Merck is currently launching more than 10 medicines in key markets around the world.
•The company continues to make progress in its pipeline, including:
- Boceprevir, an investigational oral hepatitis C virus (HCV) protease inhibitor, was granted Priority Review status by the U.S. Food and Drug Administration (FDA) and accelerated assessment status by the European Union.
- The FDA accepted a new drug application for an investigational extended-release formulation of JANUMET (sitagliptin/metformin HCI).
- In the Phase III DEFINE study with Merck's investigational CETP inhibitor, anacetrapib, patients with coronary heart disease or CHD risk equivalents showed no significant differences from placebo in the primary safety measures studied. In addition, at 24 weeks, anacetrapib decreased LDL-C (bad cholesterol) by 40 percent and increased HDL-C (good cholesterol) by 138 percent in patients already treated with a statin and at guideline-recommended LDL-C goal.
- Top-line results for Phase III SUCCEED trial of ridaforolimus showed it met the primary endpoint in patients with metastatic soft-tissue or bone sarcomas
This sums up big pharma, and our partner Merck real well:
http://www.minyanville.com/businessmarkets/articles/pfizer-merger-merck-merger-m2526a-stock/2/2/2011/id/32576?camp=syndication&medium=portals&from=yahoo
Blackrock now owns 7% of Ariad, 8,973,124 shares
A back to the woodshed day.. If Merck doesn't say anything about Rida tomorrow, I will reduce holdings...
Here comes a rash of Form 4 Ariad option transactions at a price of zero, but an exercise price of $6.38
Sure looks like a base to me
LOX and bagles truly has a new meaning to me now...
Motley Fool is terrible, and here is another:
http://finance.yahoo.com/q/bc?s=TST&t=5y&l=on&z=l&q=l&c=
BioTechHedge, I think you answered your question in your first paragraph with your second paragraph..
I find it unconscionable that with the outstanding results of Rida in the endometral trials, that Merck hasn't leveraged off this and said SOMETHING about moving this forward to help patients with this dreaded condition.
Indeed! I sure hope Ariad partners Pona ex US, AND '113 with another biotech, and not big old pharma.. Need a partner with at least a little fire in their belly..
Bellweather, it maybe as simple is that Merck doesn't have a plan quite yet. I think the Endo results are certainly good enough to move to a phase III trial in a VERY difficult cancer to treat.. What an opportunity for them to have a first mover advantage... it just takes time
They probably just don't have all their ducks aligned in order yet.. However, time is ah' wasting..
Sure would like to see some "official" statements from Merck on what they plan to do with Rida.. Filing plans for the Sarcoma NDA, moving to phase III for endo? Prostate? Lung?
This has been just Ariad's show for some reason..
Adam Feuerstein comments on Ariad.. Maybe someone should email Adam Don's summary on possible catalysts to help him out. No time for me..
http://www.thestreet.com/_yahoo/story/10987614/1/biotech-stock-mailbag-orexigen-therapeutics.html?cm_ven=YAHOO&cm_cat=FREE&cm_ite=NA
I'm pleased with the three best-in-class compounds. Harvey never mentioned a fourth candidate.
Well, the outstanding Tim Clackson at Ariad is British, so he maybe able to ring them up for a chat. 4th biologic compound?
I thought this was the Ariad board? Moderator?
Looks like the mo-mo crowd has jumped aboard!
The only knock against the article are the revenue estimates..they are virtually impossible to achieve in the short timeframe he has laid out..
Ariad- genie is about to come out of a bottle...
http://seekingalpha.com/article/248175-genie-about-to-come-out-of-ariad-s-bottle?source=yahoo
Don, could you please re-post your list of events that could impact Ariad's share price over the next 12 to 24 months? It was removed from the sticky list due to the Jefferies note.
Thanks..
That's what I was thinking.. a mixed shelf of debt and equity.
So, for a time line (opmistically), it looks like we have FDA approval for Rida in Sarcoma in the first half of 2012, and the FDA NDA filing in the second half of 2012 for Ponat. Don, without partnering in the EU and Asia for Ponat, isn't one more dilution needed for Ariad to make it to the promised land?
Federal officials concerned about the slowing pace of new drugs coming out of the pharmaceutical industry have decided to start a billion-dollar government drug development center to help create medicines.
http://finance.yahoo.com/news/Federal-center-hopes-to-spur-apf-1577490847.html?x=0&sec=topStories&pos=main&asset=&ccode=
For those that missed it, this is the essence of the last post:
The Johns Hopkins team also found that 14 percent of the samples studied contained mutations in a gene family called mTOR, which regulates cell signaling processes. Papadopoulos says that patients with tumors containing such alterations in the mTOR pathway could be candidates for treatment with mTOR inhibitor drugs.
"This is a great example of the potential for personalized cancer therapy," says Hruban. "Patients who are most likely to benefit from a drug can be identified and treated, while patients whose tumors lack changes in the mTOR pathway could be spared the side effects of drugs that may not be effective in their tumors
PGS, you are right.. I thought that was a stretch..
I now have a pretty good understanding what it means to being brought behind the woodshed....
No question that it was cleared by Merck. I guess I'm just disappointed that Merck felt that it wasn't important enough to participate in a joint release with Ariad. (After all, they do own the compound, for heaven sakes..) Could it be they thought the results were marginal?? I don't know..
I'm quite confident he said, "no partnership discussions until AFTER Rida results".
Partnerships in the EU and Asia.
We should be VERY concerned that it was not a joint Merck/Ariad press release. Why, why??
I heard they wanted USA only.. Just like Rida, originally..
G, that will be virtually, and actually, impossible.....
Be thankful you own Ariad and not Mannkind (MNKD) Inhaled Insulin Treatment
Just think of those buyers at $7.32 yesterday! I hope it was a "short term tax loss" trade, and not a hold.. But, we know the answer to that...
It's called profit taking..nothing more, nothing less..
The question is, will Mr. Market connect the dots with all the other Ridaforolimus trials in the pipeline with Merck and Ariad and continue the momentum, or do we get a temporary pull back? I expect there is no looking back..
poorgradstudent, thank you for that reply as I'm sure it answered a question that a number of individuals on this board had.. You are not so poor after all as I'm discovering...
I would be surprised if they postpone it again this late in the game.. We will know the efficacy before the end of Q1 2011, IMHO
I would guess that it is three months to dot the I's and cross the T's and get it into the final package.. Question. Does Ariad get paid at submission or, acceptance of the NDA?
Interesting hypothesis on where we will sit in the world in the next 20 years: